The utility of genomics and functional imaging to predict Irinotecan and Sunitinib pharmacokinetics and pharmacodynamics

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/628564

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Cancer patients have large differences in the way their liver breaks down anticancer drugs, leading to a poor tumor response or severe side effects. This project will be with 2 cancer drugs which can cause severe side effects. Patients will have special liver Xrays to check their liver function and have blood taken to look at DNA or genes important in drug breakdown and action. These genes and imaging may help identify patients at risk of severe toxicity or poor response and optimise drug use.

Funded Activity Details

Start Date: 01-01-2010

End Date: 01-01-2015

Funding Scheme: NHMRC Project Grants

Funding Amount: $815,733.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Clinical Pharmacology and Therapeutics

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

Cancer Chemotherapy | Drug Toxicity | Functional imaging | Oncology | Pharmacodynamics | Pharmacokinetics | Phenotype Genotype Correlation | Polymorphic enzymes

Related Links